New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
13:43 EDTOREXOrexigen Therapeutics volatility elevated into PDUFA
Orexigen Therapeutics June call option implied volatility is at 164, July is at 116, October is at 88; compared to its 26-week average of 81 according to Track Data, suggesting large movement into the PDUFA goal date of June 10 for Contrave.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:21 EDTOREXOrexigen Contrave sales encouraging, says RBC Capital
Subscribe for More Information
07:22 EDTOREXOrexigen Contrave off to strong start, says JMP Securities
Subscribe for More Information
February 25, 2015
06:33 EDTOREXOrexigen reports Q4 EPS 0c, consensus 21c
Subscribe for More Information
February 24, 2015
09:03 EDTOREXUltragenyx adds Orexigen CEO to board
Ultragenyx Pharmaceutical (RARE) announced the appointment of Michael Narachi to the company's board, effective February 20. Narachi, President and CEO and a director of Orexigen Therapeutics (OREX), will serve as an independent director to Ultragenyx.
08:10 EDTOREXOrexigen resumed with an Outperform at Leerink
Target $8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use